Healthcare and Pharmaceuticals INDUSTRIES

WilmerHale's lawyers offer exceptional experience assisting healthcare providers, healthcare insurers and the companies that supply them with specialized products and services across a broad range of specialties. These specialties include fraud investigations and litigation; data protection and privacy; patent and trademark prosecution and litigation; transactions; antitrust; regulatory, legislative and public policy counseling; and commercial litigation. Our lawyers also include leading healthcare practitioners in the EU and China.

The healthcare industry accounts for nearly one-fifth of the US economy. In the EU, healthcare spending is expected to rise to nearly 15% of GDP by 2030. Our lawyers—who include the former general counsel of one of the largest health insurers in the country and senior in-house lawyers from an array of life sciences companies—know the industry from the inside.  

Experience

With the adoption of the Affordable Care Act, the US healthcare system—and the legal regime governing it—are undergoing dramatic changes. Major regulatory innovations are also advancing overseas. Our lawyers bring experience serving in senior roles in government and hands-on knowledge of how the government works in advising clients on the many issues affecting healthcare companies that have a government component. Our group includes individuals who have served in the Justice Department, including in its Antitrust Division, the Federal Trade Commission, the White House and on the staffs of Senators who have been the leading voices on healthcare policy issues.

Our healthcare group brings together specialists in many fields of greatest use to companies and organizations in the healthcare sector:

  • Healthcare Investigations/Enforcement Litigation. WilmerHale has been involved in some of the most significant healthcare-related, criminal and civil investigations and litigation during the last decade. We frequently represent clients in investigations, leveraging the knowledge of our deep bench of former Justice Department officials, including two former Deputy Attorneys General, a former Assistant Attorney General in charge of the Civil Division, a former US Attorney and numerous Assistant US Attorneys.
  • Public Policy and Congressional & Executive Branch Investigations. Operating at the intersection of law, policy and politics, WilmerHale’s lawyers represent clients in high-stakes congressional and executive-branch investigations, help them shape legislation and regulations and guide them through the political and media mazes that often accompany public policy controversies.
  • Transactional and Corporate. WilmerHale’s lawyers are renowned for their work on mergers and acquisitions, IPO’s, private equity deals, strategic alliances and corporate governance matters both domestically and in the EU and China. We provide a one-stop source for solutions to the diverse array of corporate issues facing healthcare and life-sciences clients.
  • Patent and Trademark Prosecution and Litigation. WilmerHale’s patent litigation practice is second-to-none, garnering numerous national awards for consistently winning headline-grabbing cases. Our patent prosecution team has filed thousands of US and foreign patent applications. And our trademark lawyers are equally adept at registration and litigation.
  • Data Security and Privacy. Our firm offers significant experience navigating the complex waters of data security and privacy laws, including HIPAA, the HITECH Act and FTC medical data breach notification requirements. From advising on domestic and global regulatory issues to litigating nuanced questions of first impression, to shaping compliance regimes, our lawyers provide soup-to-nuts counsel to our clients.
  • Antitrust. Our antitrust and competition lawyers counsel companies on the full spectrum of antitrust issues in jurisdictions across the United States and around the globe. Our deep knowledge of securing merger clearance should put us at the top of the list for any healthcare company facing acquisition decisions.
  • Commercial Litigation. Our philosophy is simple: Consistent courtroom excellence is essential to client satisfaction in the resolution of high-stakes commercial disputes like the ones we litigate. We have extensive experience litigating a wide variety of complex civil cases, including ERISA matters.
  • EU/Germany. Advising on regulatory, public policy, and legal strategy questions in the German healthcare arena as well as in the rest of the European Union, our partners offer pharmaceutical companies, producers of medical devices, associations of physicians and other healthcare clients a full-services approach to tackling questions of public law, privacy, transactional, licensing, and other types of law as well as public policy and legal strategy advice.
  • China. WilmerHale offers companies around the world extensive experience and understanding of the Chinese legal and policy systems and their impact on the healthcare, pharmaceuticals and medical device industries. We also handle a wide range of acquisitions and other corporate transactions and provide unparalleled insight on market access questions.

Publications & News

View

October 19, 2017

WilmerHale Reps Cydan in Raising $34M to Accelerate New Treatments for Rare Genetic Diseases

Cydan, the first orphan drug accelerator dedicated to advancing therapies that improve the lives of patients with rare genetic diseases, announced a new round of financing, raising a committed total of $34 million to advance the company's efforts to create new and innovative therapies for patients living with rare genetic diseases.

October 17, 2017

WilmerHale Advises Visterra in $46.7M Series C Financing

Visterra, Inc., a clinical-stage biotechnology company that uses its novel Hierotope® platform to identify unique disease targets, announced that it has completed a Series C financing round raising a total of $46.7 million, including a new extension totaling $23.6 million.

October 5, 2017

WilmerHale Reps Disarm Therapeutics in $30M Series A Financing

Disarm Therapeutics, a new biotechnology company developing therapeutics to treat patients with neurological diseases by preventing axonal degeneration, announced the recent completion of a $30 million Series A financing.

October 3, 2017

WilmerHale Counsels Suono Bio in Seed Funding Led by Polaris and MIT’s The Engine

Suono Bio, a company developing a platform technology designed to enable ultra-rapid delivery of therapeutics—including proteins and nucleic acids—to the gastrointestinal tract, has announced that it has raised its seed funding round from Polaris, MIT's “The Engine” and other investors.

September 29, 2017

Epizyme Announces Closing of Public Offering of Common Stock

Epizyme, Inc., a clinical-stage biopharmaceutical company creating novel epigenetic therapies, announced the closing of its public offering of 10,557,000 shares of its common stock.

September 28, 2017

WilmerHale Reps Nabriva Therapeutics in $80M Public Offering of Ordinary Shares

On September 22, 2017, Nabriva Therapeutics plc closed on its underwritten public offering of 9,411,765 ordinary shares at a public offering price of $8.50 per share, totaling approximately $80 million.

August 30, 2017

WilmerHale Reps Apellis Pharmaceuticals in $60 Million Series E Financing

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, announced the closing of a $60 million Series E preferred stock financing.

August 7, 2017

WilmerHale Reps Tetraphase Pharmaceuticals in $65M Public Offering of Common Stock

Tetraphase Pharmaceuticals, Inc. has closed on an underwritten public offering of 10,000,000 shares of its common stock for a public offering price of $6.50 per share, with gross proceeds of $65 million.

July 31, 2017

BTI Industry Power Rankings Feature WilmerHale’s Strong Client Relationships in Key Industries

WilmerHale registers an impressive performance in the BTI Industry Power Rankings 2017, which provides insight into the law firms that are best positioned with the largest, most prestigious clients across 18 industry segments.

July 27, 2017

WilmerHale Represents Kala Pharmaceuticals in $103.5 Million IPO

On July 25, 2017, Kala Pharmaceuticals, Inc. announced the closing of its initial public offering of 6,900,000 shares of common stock, including the underwriters' exercise in full of their option to purchase an additional 900,000 shares, at the public offering price of $15.00 per share.